SLC2A1 and head and neck squamous cell carcinoma: To evaluate the in vivo effects of GLUT1 inhibition in HNSCC, we first treated SCID mice bearing FaDu xenograft tumors with either WZB117 (10 mg/kg daily) or BAY-876 (4.5 mg/kg daily) for 2 weeks and observed that both inhibitors significantly reduced tumor growth compared with vehicle-treated controls (Fig. 5C; Supplementary Fig. S2A).